RecruitingNCT05612906
Renal Nerve Denervation(RDN) and Renal Function
Effect of RDN on Renal Function
Sponsor
Zhengrong Huang
Enrollment
50 participants
Start Date
Jun 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Current studies have found the efficacy of RDN in the treatment of hypertension, however, the safety of RDN in renal function is still lacking. Therefore, the investigators are aimed to study the effect of RDN on renal function.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- 18<age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.
Exclusion Criteria5
- pregnant women or lactating patients;
- identified secondary hypertension or Pseudo hypertension;
- whose renal arteries were unsuitable for ablation
- obvious bleeding tendency and blood system diseases;
- malignant tumors or end-stage diseases; ⑥Severe peripheral vascular disease, abdominal aortic aneurysm; ⑦A history of the acute coronary syndrome within two weeks; ⑧acute or severe systemic infection; ⑨drug or alcohol dependence or refusal to sign informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05612906